Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xalnesiran
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Xalnesiran (RO7445482, RG6346) is a GalNAc-conjugated small interfering RNA (siRNA) therapeutic developed by Roche (following its acquisition of Dicerna Pharmaceuticals) for the treatment of chronic hepatitis B virus (HBV) infection. The drug utilizes the RNA interference (RNAi) pathway to target a highly conserved S region of the HBV genome, effectively silencing all HBV transcripts (including mRNA and pre-genomic RNA). This action leads to a profound and durable reduction in the production of viral proteins, most notably the hepatitis B surface antigen (HBsAg), which is a key factor in viral persistence and immune evasion. Xalnesiran is currently being investigated in Phase 2 clinical trials, such as the Piranga platform study, where it is evaluated as a monotherapy and in combination with other agents like TLR7 agonists or pegylated interferon to achieve a functional cure.
- Brand names
- xalnesiran
- Other names
- xalnesiran sodium
02
Targets
HBV RNA (Hepatitis B virus RNA)
Beyond the preview
Go deeper on xalnesiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xalnesiran.